Skip to Main Content

Paper Details

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
Clin Cancer Res
10
2023
MMR-proficient tumor, MMRD, Mismatch Repair Deficiency, Nivolumab, Pediatric Cancers, TMB, cancer, children, hypermutated cancers, malignant gliomas, mismatch repair deficiency, mutations, nonhematologic cancers, patient, patients, regulatory circulating T cells, solid and brain tumors, tumor
Author NameAffiliation
Uri TaboriHospital for Sick Children and Department of Paediatrics, University of Toronto
Rebecca J DeyellBC Children's Hospital
Jane E MinturnChildren's Hospital of Philadelphia
Gad GetzBroad Institute of Harvard and MIT
Gad GetzBroad Institute of Harvard and MIT
Birgit Ertl-WagnerHospital for Sick Children and Department of Paediatrics, University of Toronto
Trevor J PughPrincess Margaret Cancer Centre and University of Toronto
Trevor J PughPrincess Margaret Cancer Centre and University of Toronto
Cynthia HawkinsHospital for Sick Children and Department of Paediatrics, University of Toronto
Cynthia HawkinsHospital for Sick Children and Department of Paediatrics, University of Toronto
Eric BouffetHospital for Sick Children and Department of Paediatrics, University of Toronto
  • 1 - 11

Datasets

Release 1.2